Part 7/8:
As the industry awaits the FDA's final decision slated for May 26th, according to Campbell, the stakes could not be higher for Sarepta. If approved, the company may still need to conduct a confirmatory trial while also preparing to serve a patient population desperate for new treatment options. Conversely, a negative decision could put Sarepta in a precarious position, forcing the company to contemplate investing in costly and time-consuming studies to reacquire FDA approval.
With $192 million in cash and operating expenses recorded at $220 million the previous year, the company's financial health may significantly impact its ability to navigate these next steps. The uncertainty surrounding outcomes and investment risks make Sarepta a high-stakes wager for investors.